NCT05538949View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Healthy
Interventions
DRUG

EB-203

"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."

DRUG

Placebo

Placebo 1Drop, QD / Day1, BID / Day5\~Day8.

Trial Locations (1)

47392

Busan Paik Hospital, Inje University, Busan

All Listed Sponsors
lead

EyebioKorea, Inc.

INDUSTRY